On January 5, 2022 OWP Pharmaceuticals, Inc. is a privately held, neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations and supporting global philanthropy (Press release, EVERSANA, JAN 5, 2022, View Source [SID1234598310]). Today OWP reported its partnership with EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, to launch and commercialize its portfolio of oral liquid formulations aimed to treat neuroscience disorders.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pending regulatory approvals, OWP has multiple specialty pharmaceutical products in development. Most recently, OWP announced IND authorization for the first-ever oral liquid formulation of atomoxetine hydrochloride for the treatment of attention deficit hyperactivity disorder. OWP has also received patent issuance or IND authorization for multiple therapies for the treatment of epilepsy, schizophrenia, bipolar disorder, major depressive and generalized anxiety disorder, and migraines.
OWP will utilize many of EVERSANA’s fully integrated commercialization services that include market access, agency services, clinical and commercial field teams, channel management, patient services, health economics and outcomes research, and compliance, with each service optimized by data and predictive analytics.
"With EVERSANA’s integrated commercialization solution, we are ensuring that our products will get to patients efficiently and effectively as we anticipate multiple regulatory approvals in 2023 and beyond," said Scott Boyer, Founder and President, OWP.
"The unmet need for better neuroscience treatments demands our attention," said Jim Lang, Chief Executive Officer of EVERSANA. "Our EVERSANA COMPLETE end-to-end commercialization engine will be ready to move swiftly in anticipation of FDA submissions and approvals."